We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Read MoreHide Full Article
For Immediate Release
Chicago, IL –August 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk (NVO - Free Report) , J&J (JNJ - Free Report) , Allergan , Editas Medicine, Inc. (EDIT - Free Report) , AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
After robust earnings performance by pharma bigwigs in the past couple of weeks, it was a relatively quiet period for the sector. Novo Nordisk beat estimates for both earnings and sales in the second quarter. J&J filed regulatory applications to get the label of its multiple myeloma drug, Darzalex updated to include a split dosing regimen. Allergan exercised its option to buy development/commercialization rights to Editas Medicine, Inc.’s lead CRISPR genome-editing ocular therapy, EDIT-101.
Recap of the Week’s Most Important Stories
Novo Nordisk Q2 Earnings & Sales Beat: Novo Nordisk beat estimates for both earnings and sales in the second quarter. Earnings per American depositary receipt of 68 cents were higher than 59 cents earned in the year-ago period. Total revenues of $4.38 billion rose 2% in local currency. While sales in the Diabetes and Obesity Care segment rose 4% in local currency, the same in Biopharmaceuticals segment declined 4%.
J&J Seeks Approval for Split Dosing Regimen of Darzalex: J&J filed regulatory applications in both the United States and EU for label expansion of its multiple myeloma drug, Darzalex. J&J is looking to get the label of Darzalex updated to allow prescribing the medicine by splitting the first infusion of Darzalex over two consecutive days. Approval for this split dosing option is likely to improve the administration profile of the medicine.
Allergan Buys Ocular Candidate from Editas: Allergan exercised its option for the discovery and development of genome editing company Editas’ lead CRISPR genome-editing ocular therapy, EDIT-101. It is being developed for Leber congenital amaurosis (LCA10), a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness. For exercising the option, Allergan paid Editas a fee of $15 million per their deal in March last year. Allergan is now responsible for development and commercialization of EDIT-101.
AstraZeneca/Merck’s Selumetinib Granted Orphan Designation in Europe: AstraZeneca and partner Merck announced that their MEK 1/2 inhibitor, selumetinib has been granted orphan designation by the European Medicines Agency (EMA) for the treatment of neurofibromatosis type 1 (NF1), an incurable genetic condition that affects newborns. This designation is assigned to drugs, which are intended to treat rare disease.
In the past six months, Lilly has been the biggest gainer (34.0%) while Bristol-Myers declined the most (5.8%).
What's Next in the Pharma World?
Watch out for several pipeline and regulatory updates next week
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
For Immediate Release
Chicago, IL –August 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk (NVO - Free Report) , J&J (JNJ - Free Report) , Allergan , Editas Medicine, Inc. (EDIT - Free Report) , AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
After robust earnings performance by pharma bigwigs in the past couple of weeks, it was a relatively quiet period for the sector. Novo Nordisk beat estimates for both earnings and sales in the second quarter. J&J filed regulatory applications to get the label of its multiple myeloma drug, Darzalex updated to include a split dosing regimen. Allergan exercised its option to buy development/commercialization rights to Editas Medicine, Inc.’s lead CRISPR genome-editing ocular therapy, EDIT-101.
Recap of the Week’s Most Important Stories
Novo Nordisk Q2 Earnings & Sales Beat: Novo Nordisk beat estimates for both earnings and sales in the second quarter. Earnings per American depositary receipt of 68 cents were higher than 59 cents earned in the year-ago period. Total revenues of $4.38 billion rose 2% in local currency. While sales in the Diabetes and Obesity Care segment rose 4% in local currency, the same in Biopharmaceuticals segment declined 4%.
J&J Seeks Approval for Split Dosing Regimen of Darzalex: J&J filed regulatory applications in both the United States and EU for label expansion of its multiple myeloma drug, Darzalex. J&J is looking to get the label of Darzalex updated to allow prescribing the medicine by splitting the first infusion of Darzalex over two consecutive days. Approval for this split dosing option is likely to improve the administration profile of the medicine.
Allergan Buys Ocular Candidate from Editas: Allergan exercised its option for the discovery and development of genome editing company Editas’ lead CRISPR genome-editing ocular therapy, EDIT-101. It is being developed for Leber congenital amaurosis (LCA10), a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness. For exercising the option, Allergan paid Editas a fee of $15 million per their deal in March last year. Allergan is now responsible for development and commercialization of EDIT-101.
AstraZeneca/Merck’s Selumetinib Granted Orphan Designation in Europe: AstraZeneca and partner Merck announced that their MEK 1/2 inhibitor, selumetinib has been granted orphan designation by the European Medicines Agency (EMA) for the treatment of neurofibromatosis type 1 (NF1), an incurable genetic condition that affects newborns. This designation is assigned to drugs, which are intended to treat rare disease.
In the past six months, Lilly has been the biggest gainer (34.0%) while Bristol-Myers declined the most (5.8%).
What's Next in the Pharma World?
Watch out for several pipeline and regulatory updates next week
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.